Can rifabutin, amoxicillin, or pantoprazole cause Stevens-Johnson syndrome, and what is the likelihood?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Rifabutin, Amoxicillin, or Pantoprazole Cause Stevens-Johnson Syndrome?

Yes, all three medications can cause Stevens-Johnson syndrome (SJS), but the risk varies significantly: amoxicillin carries a well-documented risk as an antibiotic class member, pantoprazole has rare but confirmed case reports, and rifabutin is explicitly labeled by the FDA as causing severe cutaneous adverse reactions including SJS.

Risk Assessment by Medication

Amoxicillin - Established High-Risk Agent

Amoxicillin is contraindicated in patients with prior serious hypersensitivity reactions including Stevens-Johnson syndrome 1. The FDA drug label explicitly warns that amoxicillin may cause severe cutaneous adverse reactions (SCAR), including SJS, toxic epidermal necrolysis (TEN), DRESS, and AGEP 1.

Likelihood and Clinical Evidence:

  • Antibiotics, particularly amoxicillin, are among the most common drug triggers for SJS/TEN in both adults and children 2
  • Recent pharmacovigilance analysis of 78,593 infected patients identified amoxicillin as having a significant positive risk signal for SJS/TEN 3
  • A systematic review found 64 documented cases of amoxicillin-associated SJS/TEN, with 46.9% developing TEN and 43.8% developing SJS 4
  • Median hospital stay was 16 days (range 3-70 days), with frequent serious complications, long-term sequelae, and high mortality 4
  • SJS/TEN can occur promptly after starting amoxicillin or as a delayed adverse effect 5, 6

Critical timing: The typical latency period is 5-28 days after drug initiation, though it may be shorter with prior exposure 7.

Rifabutin - FDA-Confirmed Risk

The FDA drug label explicitly states that rifabutin has been associated with severe cutaneous adverse reactions (SCARs) including DRESS, SJS, TEN, and AGEP 8.

Likelihood:

  • While specific incidence rates are not provided in the label, rifabutin is officially recognized as causing these life-threatening reactions
  • The drug label warns that pyrexia, rash, eosinophilia, and bronchospasm may occur as hypersensitivity reactions 8
  • Post-marketing surveillance has confirmed these associations 8

Pantoprazole - Rare but Documented Risk

Pantoprazole can cause SJS, though it is considerably rarer than antibiotic-induced cases.

Likelihood:

  • Proton pump inhibitors are rarely reported as causative agents in SJS 9
  • Only sporadic cases secondary to pantoprazole have been documented in the literature 9
  • A 2024 case report confirmed pantoprazole-induced SJS with complete resolution after drug withdrawal 9
  • The incidence is substantially lower than antibiotics or anticonvulsants, which are the primary drug triggers 2

Comparative Risk Hierarchy

From highest to lowest risk:

  1. Amoxicillin - Well-established, frequent cause among antibiotics
  2. Rifabutin - FDA-confirmed SCAR risk, though less commonly prescribed
  3. Pantoprazole - Rare but documented; generally well-tolerated

Clinical Implications and Monitoring

Immediate discontinuation of any suspected medication is critical, as this decreases the risk of death 2.

Key warning signs to monitor:

  • Cutaneous pain (prominent early feature) 2
  • Tender skin with positive Nikolsky sign 2
  • Mucosal involvement (oral, ocular, genital) 2
  • Progression from papular to vesicular lesions 6
  • Target-like lesions with bullous centers 9

High-risk populations requiring extra vigilance:

  • Patients with prior penicillin hypersensitivity 1
  • Those with history of multiple drug allergies 1
  • Patients with pneumonia, urinary tract infections, or sepsis (higher risk with antibiotics) 3
  • Male patients may have higher risk with certain antibiotics 3

Common Pitfalls to Avoid

  • Do not dismiss early rash as benign - SJS/TEN can be misdiagnosed initially (e.g., as chickenpox) 6
  • Do not continue the drug while "monitoring" - immediate discontinuation is essential 2, 1
  • Do not overlook drug timing - use tools like www.drugrash.co.uk to establish temporal relationship 7
  • Do not assume prior tolerance means safety - SJS can occur even after previous uneventful exposures 5

If skin rash develops on any of these medications, patients should be monitored closely and the drug discontinued if lesions progress 1.

References

Related Questions

Can Stevens-Johnson syndrome be caused by Zosyn (piperacillin‑tazobactam), and which alternative antibiotic for cellulitis has minimal risk of Stevens-Johnson syndrome?
What are the early signs of Stevens-Johnson syndrome (SJS) and when should a patient be referred to the emergency department?
With an estimated glomerular filtration rate of 34 mL/min/1.73 m² and a serum creatinine of 159 µmol/L, can the patient receive co‑amoxiclav (amoxicillin/clavulanic acid) 625 mg every 12 hours?
In early Stevens-Johnson syndrome, if the patient is stable without severe symptoms, should they still go to the emergency department, or is it reasonable to stop the offending drug and monitor as an outpatient?
Can oseltamivir cause Stevens‑Johnson syndrome (SJS)?
Does graft-versus-host disease (GVHD) increase the risk of developing a second primary hematologic malignancy?
Can carpal tunnel syndrome be work‑related?
What is the appropriate treatment for distal coccygeal subluxation?
What clinical, laboratory, and imaging criteria define a Crohn's disease flare?
Which of the following statements about metabolic alkalosis is NOT true?
How do changes in arterial carbon dioxide tension (PaCO₂) or the venous‑arterial CO₂ gap (Pv‑aCO₂) predict whether a patient is fluid‑responsive with respect to cardiac output after a fluid challenge?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.